Posts Tagged ‘pharma’
Icagen doing better
Tuesday, August 4, 2009, 4:45 am No Comments | Post a CommentAfter months of wrangling with an influential investor — the argument included calls for the resignation of the chief executive — things are looking up again at Icagen, a Durham company working on painkillers and asthma and epilepsy treatments.
At least for the moment they are.
Next: A crucial decision
Tuesday, July 28, 2009, 9:14 am No Comments | Post a CommentThis is the last part. Continued from part 2.
Developing medicines is a minefield that Tranzyme Pharma has navigated well so far. But the Durham company is about to embark on one of its trickiest missions.
BDSI stock drops on Onsolis approval
Friday, July 17, 2009, 12:19 pm No Comments | Post a CommentGetting its first product, a painkiller, approved for sale was a triumph for BioDelivery Sciences.
Champagne corks popped at BDSI Thursday, the day the Food and Drug Administration let the small Raleigh drug development company know that Onsolis, a potent pain patch for cancer patients, had passed all regulatory hurdles. On Friday, analysts congratulated BDSI CEO Mark Sirgo during a conference call. By Monday, BDSI expected to have about $27 million more in the bank, a payment its Swedish partner Meda promised upon regulatory approval of Onsolis.
“It’s been a long haul,” Sirgo told analysts in the call Friday. “This is a fantastic day for our company.”
So why did BDSI’s stock drop 5 percent on a day when it should have risen?
Getting a ghrelin drug to market
Tuesday, July 14, 2009, 11:38 am No Comments | Post a CommentThis is the second part of three. Continued from part 1.
Work on promising ghrelin medicines has gotten to a critical stage a decade after Japanese researchers discovered the hormone that stimulates hunger and is linked to insulin production.
Cornerstone zeros in on a deal
Tuesday, July 14, 2009, 7:19 am No Comments | Post a CommentCornerstone Therapeutics, a Cary company that specializes in respiratory therapies, has offered to pay $5 million for the commercial rights to Factive, a respiratory anitbiotic that generated $16 million in sales last year.
